Efficacy and safety of olmesartan medoxomil versus valsartan in Chinese patients with mild to moderate essential hypertension

Objective To evaluate the efficacy and safety of olmesartan medoxomil compared with valsartan in patients with mild to moderate essential hypertension. Methods A total 240 eligible subjects were randomized at 1∶1 ratio to receive olmesartan medoxomil 20-40 mg or valsartan 80-160 mg,once daily for 8 weeks. Results The mean trough reduction in SeDBP from baseline was no difference between olmesartan medoxomil and valsartan groups after 4 weeks \[(10.58±6.82) mmHg vs (9.38±7.16) mmHg,P0.05\] and 8 weeks treatment \[(15.72±6.03) mmHg vs (14.12±6.79) mmHg,P0.05\]. After 4 weeks treatment,the patients with double dose in olmesartan and valsartan group were 60% and 61.74%,the double dose efficiency were 52.22% and 51.85% respectively(P0.05). The incidence of study drug-related adverse event (AE) in olmesartan group (3.33%) was similar to that in valsartan group (7.5%,P0.05). No SAE was occurred. Conclusion Olmesartan medoxomil at oral dase of 20~40 mg once daily was effective and safe for hypertension treatment and effect was similar to valsartan 80~160 mg once daily.